413 related articles for article (PubMed ID: 27285982)
1. Novel cancer stem cell targets during epithelial to mesenchymal transition in PTEN-deficient trastuzumab-resistant breast cancer.
Sun L; Burnett J; Gasparyan M; Xu F; Jiang H; Lin CC; Myers I; Korkaya H; Liu Y; Connarn J; He H; Zhang N; Wicha MS; Sun D
Oncotarget; 2016 Aug; 7(32):51408-51422. PubMed ID: 27285982
[TBL] [Abstract][Full Text] [Related]
2. Trastuzumab resistance induces EMT to transform HER2(+) PTEN(-) to a triple negative breast cancer that requires unique treatment options.
Burnett JP; Korkaya H; Ouzounova MD; Jiang H; Conley SJ; Newman BW; Sun L; Connarn JN; Chen CS; Zhang N; Wicha MS; Sun D
Sci Rep; 2015 Nov; 5():15821. PubMed ID: 26522776
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients.
De Mattos-Arruda L; Bottai G; Nuciforo PG; Di Tommaso L; Giovannetti E; Peg V; Losurdo A; Pérez-Garcia J; Masci G; Corsi F; Cortés J; Seoane J; Calin GA; Santarpia L
Oncotarget; 2015 Nov; 6(35):37269-80. PubMed ID: 26452030
[TBL] [Abstract][Full Text] [Related]
4. Notch-1-PTEN-ERK1/2 signaling axis promotes HER2+ breast cancer cell proliferation and stem cell survival.
Baker A; Wyatt D; Bocchetta M; Li J; Filipovic A; Green A; Peiffer DS; Fuqua S; Miele L; Albain KS; Osipo C
Oncogene; 2018 Aug; 37(33):4489-4504. PubMed ID: 29743588
[TBL] [Abstract][Full Text] [Related]
5. Cancer stem cell-targeted therapeutic approaches for overcoming trastuzumab resistance in HER2-positive breast cancer.
Qiu Y; Yang L; Liu H; Luo X
Stem Cells; 2021 Sep; 39(9):1125-1136. PubMed ID: 33837587
[TBL] [Abstract][Full Text] [Related]
6. A small-molecule inhibitor of SMAD3 attenuates resistance to anti-HER2 drugs in HER2-positive breast cancer cells.
Chihara Y; Shimoda M; Hori A; Ohara A; Naoi Y; Ikeda JI; Kagara N; Tanei T; Shimomura A; Shimazu K; Kim SJ; Noguchi S
Breast Cancer Res Treat; 2017 Nov; 166(1):55-68. PubMed ID: 28702892
[TBL] [Abstract][Full Text] [Related]
7. Epithelial-to-mesenchymal transition (EMT) confers primary resistance to trastuzumab (Herceptin).
Oliveras-Ferraros C; Corominas-Faja B; Cufí S; Vazquez-Martin A; Martin-Castillo B; Iglesias JM; López-Bonet E; Martin ÁG; Menendez JA
Cell Cycle; 2012 Nov; 11(21):4020-32. PubMed ID: 22992620
[TBL] [Abstract][Full Text] [Related]
8. Downregulation of LncRNA GAS5 causes trastuzumab resistance in breast cancer.
Li W; Zhai L; Wang H; Liu C; Zhang J; Chen W; Wei Q
Oncotarget; 2016 May; 7(19):27778-86. PubMed ID: 27034004
[TBL] [Abstract][Full Text] [Related]
9. MTDH mediates trastuzumab resistance in HER2 positive breast cancer by decreasing PTEN expression through an NFκB-dependent pathway.
Du C; Yi X; Liu W; Han T; Liu Z; Ding Z; Zheng Z; Piao Y; Yuan J; Han Y; Xie M; Xie X
BMC Cancer; 2014 Nov; 14():869. PubMed ID: 25417825
[TBL] [Abstract][Full Text] [Related]
10. Basal/HER2 breast carcinomas: integrating molecular taxonomy with cancer stem cell dynamics to predict primary resistance to trastuzumab (Herceptin).
Martin-Castillo B; Oliveras-Ferraros C; Vazquez-Martin A; Cufí S; Moreno JM; Corominas-Faja B; Urruticoechea A; Martín ÁG; López-Bonet E; Menendez JA
Cell Cycle; 2013 Jan; 12(2):225-45. PubMed ID: 23255137
[TBL] [Abstract][Full Text] [Related]
11. LncRNA-ATB promotes trastuzumab resistance and invasion-metastasis cascade in breast cancer.
Shi SJ; Wang LJ; Yu B; Li YH; Jin Y; Bai XZ
Oncotarget; 2015 May; 6(13):11652-63. PubMed ID: 25871474
[TBL] [Abstract][Full Text] [Related]
12. Selective mode of action of plumbagin through BRCA1 deficient breast cancer stem cells.
Somasundaram V; Hemalatha SK; Pal K; Sinha S; Nair AS; Mukhopadhyay D; Srinivas P
BMC Cancer; 2016 May; 16():336. PubMed ID: 27229859
[TBL] [Abstract][Full Text] [Related]
13. ErbB-2 inhibition activates Notch-1 and sensitizes breast cancer cells to a gamma-secretase inhibitor.
Osipo C; Patel P; Rizzo P; Clementz AG; Hao L; Golde TE; Miele L
Oncogene; 2008 Aug; 27(37):5019-32. PubMed ID: 18469855
[TBL] [Abstract][Full Text] [Related]
14. miR-93 and PTEN: Key regulators of doxorubicin-resistance and EMT in breast cancer.
Chu S; Liu G; Xia P; Chen G; Shi F; Yi T; Zhou H
Oncol Rep; 2017 Oct; 38(4):2401-2407. PubMed ID: 28765915
[TBL] [Abstract][Full Text] [Related]
15. Lack of acquired resistance in HER2-positive breast cancer cells after long-term HER2 siRNA nanoparticle treatment.
Gu S; Ngamcherdtrakul W; Reda M; Hu Z; Gray JW; Yantasee W
PLoS One; 2018; 13(6):e0198141. PubMed ID: 29879129
[TBL] [Abstract][Full Text] [Related]
16. Activation of LncRNA TINCR by H3K27 acetylation promotes Trastuzumab resistance and epithelial-mesenchymal transition by targeting MicroRNA-125b in breast Cancer.
Dong H; Hu J; Zou K; Ye M; Chen Y; Wu C; Chen X; Han M
Mol Cancer; 2019 Jan; 18(1):3. PubMed ID: 30621694
[TBL] [Abstract][Full Text] [Related]
17. Expression of embryonal stem cell transcription factors in breast cancer: Oct4 as an indicator for poor clinical outcome and tamoxifen resistance.
Gwak JM; Kim M; Kim HJ; Jang MH; Park SY
Oncotarget; 2017 May; 8(22):36305-36318. PubMed ID: 28422735
[TBL] [Abstract][Full Text] [Related]
18. PTEN Loss Is Associated with Worse Outcome in HER2-Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance.
Stern HM; Gardner H; Burzykowski T; Elatre W; O'Brien C; Lackner MR; Pestano GA; Santiago A; Villalobos I; Eiermann W; Pienkowski T; Martin M; Robert N; Crown J; Nuciforo P; Bee V; Mackey J; Slamon DJ; Press MF
Clin Cancer Res; 2015 May; 21(9):2065-74. PubMed ID: 25649019
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of autophagy induced by PTEN loss promotes intrinsic breast cancer resistance to trastuzumab therapy.
Ning L; Guo-Chun Z; Sheng-Li A; Xue-Rui L; Kun W; Jian Z; Chong-Yang R; Ling-Zhu W; Hai-Tong L
Tumour Biol; 2016 Apr; 37(4):5445-54. PubMed ID: 26563373
[TBL] [Abstract][Full Text] [Related]
20. Inactivation of Rac1 reduces Trastuzumab resistance in PTEN deficient and insulin-like growth factor I receptor overexpressing human breast cancer SKBR3 cells.
Zhao Y; Wang Z; Jiang Y; Yang C
Cancer Lett; 2011 Dec; 313(1):54-63. PubMed ID: 21943825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]